These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19584393)

  • 1. Agreement between pharmacists for problem identification: an initial quality measurement of cognitive services.
    LaFleur J; Larson BS; Gunning KM; Stoddard GJ; Madden C; Oderda L; Steinvoort C; Oderda GM
    Ann Pharmacother; 2009 Jul; 43(7):1173-80. PubMed ID: 19584393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacists' and patients' roles in the pharmacist-patient relationship: are pharmacists and patients reading from the same relationship script?
    Worley MM; Schommer JC; Brown LM; Hadsall RS; Ranelli PL; Stratton TP; Uden DL
    Res Social Adm Pharm; 2007 Mar; 3(1):47-69. PubMed ID: 17350557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of drug-related problems identified by community pharmacies.
    Hämmerlein A; Griese N; Schulz M
    Ann Pharmacother; 2007 Nov; 41(11):1825-32. PubMed ID: 17925500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program.
    Carter BL; Chrischilles EA; Scholz D; Hayase N; Bell N
    J Am Pharm Assoc (Wash); 2003; 43(1):24-33. PubMed ID: 12585748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacists' acceptable levels of compensation for MTM services: a conjoint analysis.
    Wang J; Hong SH; Meng S; Brown LM
    Res Social Adm Pharm; 2011 Dec; 7(4):383-95. PubMed ID: 21272533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic terminology in obtaining reimbursement for pharmacists' cognitive services.
    Nutescu EA; Klotz RS
    Am J Health Syst Pharm; 2007 Jan; 64(2):186-92. PubMed ID: 17215470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive incentive program. Analysis and proposal.
    Stone J
    Am Pharm; 1986 Jul; NS26(7):45-9. PubMed ID: 3529904
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacists' views of an experience in capitation reimbursement under the Iowa Medicaid drug program.
    Cirn JT
    Contemp Pharm Pract; 1980; 3(3):180-8. PubMed ID: 10297946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and reliability testing of the clinical pharmacist recommendation taxonomy.
    Hoth AB; Carter BL; Ness J; Bhattacharyya A; Shorr RI; Rosenthal GE; Kaboli PJ
    Pharmacotherapy; 2007 May; 27(5):639-46. PubMed ID: 17461698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Billing third party payers for pharmaceutical care services.
    Poirier S; Buffington DE; Memoli GA
    J Am Pharm Assoc (Wash); 1999; 39(1):50-64; quiz 101-2. PubMed ID: 9990188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of remuneration models for pharmaceutical professional services.
    Bernsten C; Andersson K; Gariepy Y; Simoens S
    Health Policy; 2010 Apr; 95(1):1-9. PubMed ID: 19945762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting appropriate drug use through the application of the Spanish drug-related problem classification system in the primary care setting.
    Gómez MA; Villafaina A; Hernández J; Salgado RM; González MA; Rodríguez J; Martínez de la Concha M; Tarriño A; Gervasini G; Carrillo JA
    Ann Pharmacother; 2009 Feb; 43(2):339-46. PubMed ID: 19193590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of STOPP and START criteria: interrater reliability among pharmacists.
    Ryan C; O'Mahony D; Byrne S
    Ann Pharmacother; 2009 Jul; 43(7):1239-44. PubMed ID: 19584381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacist-provided immunization compensation and recognition: white paper summarizing APhA/AMCP stakeholder meeting.
    Skelton JB; ;
    J Am Pharm Assoc (2003); 2011; 51(6):704-12. PubMed ID: 22068191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principal findings from the Washington State cognitive services demonstration project.
    Christensen DB; Holmes G; Fassett WE; Neil N; Andrilla CH; Smith DH; Andrews A; Bell EJ; Hansen R; Shafer R; Stergachis A
    Manag Care Interface; 1998 Jul; 11(7):60-2, 64. PubMed ID: 10181572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events.
    MacLaren R; Bond CA
    Pharmacotherapy; 2009 Jul; 29(7):761-8. PubMed ID: 19558249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs).
    Viktil KK; Blix HS; Moger TA; Reikvam A
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):667-74. PubMed ID: 16598835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicaid reimbursement.
    Berry MD
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-31. PubMed ID: 18345577
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.